Merck KGaA Rallies Into November Earnings With Bears Firmly On The Sidelines

MRK heads into its November 12 results with the stock up 8.6% over the past month and short positioning so thin it barely registers as a factor.

The lending market tells the same story as the share price: there is no meaningful short pressure here. Availability runs at roughly 3,986% of short interest, meaning lenders have around 40 times more stock available to borrow than has been borrowed. Cost to borrow has drifted lower too, down 24% over the past month to just 0.63%. The ORTEX short score of 28.4 ranks in the 85th percentile for low short pressure, consistent with a stock where bears have little conviction. With utilization near 2.6%, and the 52-week peak only reaching 20%, there is no history of concentrated short activity to unwind. The borrow market is essentially inert.

Valuation has moved with the price. The trailing P/E has expanded to 16.8x, up around 1.1 points over the past 30 days, and EV/EBITDA has climbed to 11.4x over the same period. Price-to-book has edged up to 2.0x. None of these multiples look extreme for a large European pharma, and the earnings yield factor scores in the 82nd percentile, reflecting a stock that still offers reasonable value relative to its universe despite the recent re-rating. The dividend score of 84 stands out, though the most recent dividend data dates from early 2022 and should not be relied upon as current. Analyst data is similarly stale, with the last recorded coverage from February 2026, now more than eight months old. The mean target at that time was approximately EUR 150.8, almost exactly where the stock trades today at EUR 150.3. That convergence is notable, but given the age of those targets, they offer limited guidance on where the Street currently stands.

Ownership is the single most structurally unusual feature of Merck KGaA. E. Merck KG, the family holding entity, controls 70.3% of shares outstanding, a stake that has not changed. The remaining float is spread across a relatively small pool of institutional holders, with BlackRock at 2.1%, First Eagle at 1.5%, and MFS at 1.3%. Amundi added 361,000 shares as recently as the end of September, and Goldman Sachs Asset Management added 411,000 shares as of October 1. The family concentration means the freely traded float is narrow, which structurally suppresses short interest and limits the room for large institutional position changes in either direction.

The earnings history in the snapshot repeats the same August 2026 event across multiple entries, likely a data artefact, so no clean pattern of historical post-earnings moves can be drawn from it. What is visible is that November 12 is now 13 days away. Among the week's closest peers by price correlation, NOVN and JNJ both gained roughly 2.5% to 2.8% on the week, broadly in line with MRK's 2.7% move, while GSK dropped 5.2% and LLY surged 5.1%, illustrating how divergent individual catalysts are driving sector returns right now. MRK's quiet week, driven by its own momentum rather than any headline event, sets up the November 12 print as the first real test of whether the past month's re-rating has fundamental support.

The print on November 12 is where attention now turns, specifically whether management's commentary on the Life Science and Electronics segments can justify a P/E that has expanded by more than a point in a single month.